Skip to main content
Premium Trial:

Request an Annual Quote

Medarex to Own 32 Percent of Genmab

NEW YORK, July 25 - Genmab of Copenhagen announced today that it would issue 247,000 new shares of the company to GenPharm, a subsidiary of Medarex, leaving the Princeton, N.J.-based company with 32 percent ownership of Genmab.


The move came as a result of Genmab's decision to pay in company shares rather than in cash its annual licensing fee of $2 million to Medarex.


According to an August 2000 agreement, Genmab must pay Medarex $2 million per year through 2004 in exchange for the exclusive rights to market Medarex's transgenic mouse technologies and the right to access technologies acquired by Medarex.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.